79 Organisations

Investors

Private and institutional investors deploying capital into psychedelic companies — from early seed rounds to public-market positions.

Organisations: 79
Countries: 10

Specific Groups

Angel Investors Institutional Investors Social-Impact Investors Venture Capital

Investor Finder

Company Context

Showing 79 of 79

StageStakeholder CategoryInvestor Category

Able Partners
Able Partners is a New York City-based venture capital firm focused on early-stage consumer companies in health and wellness, with a stated emphasis on improving everyday life and wellbeing. The firm’s team page describes its partners as active investors in early-stage consumer and healthcare businesses, and its public materials frame the firm’s thesis around “positive living” and closing the wellness gap. In the psychedelic ecosystem, Able Partners is relevant because its public portfolio and investment themes include mental health, substance-use treatment, and companies building around psychedelic-adjacent care delivery. Its website also shows involvement with atai Life Sciences and Compass Pathways, suggesting exposure to the psychedelic mental-health stack alongside broader healthcare and consumer wellness bets.
View Profile
Investor Category
Venture Capital
HQ
HQ: United States
SeedSeries A/BGrowth / Late Stage
Company-Led Drug Development & CommercializationEducational Platforms & Resources
Portfolio Signals
COMPASS Pathways
Series B · undisclosed · Jan 1, 2020
Adage Capital Management
Adage Capital Management is a Boston-based institutional investment manager with deep roots in public equity investing and selective private-company participation. It is not publicly positioned as a psychedelics specialist. Its relevance to psychedelic medicine comes from confirmed exposure to Beckley Psytech and the 2025 atai/Beckley transaction financing. The record is strongest when framed as broad institutional healthcare capital entering the space opportunistically.
View Profile
Investor Category
Institutional Investors
HQ
HQ: United States
Growth / Late StagePublic MarketsMulti-StageNonprofit / grant-backed
Company-Led Drug Development & Commercialization
Portfolio Signals
Beckley Psytech
Series B · $80 million · Aug 16, 2021
AtaiBeckley
Concurrent private placement · $30.0M · Jun 2, 2025
ADAR1 Capital Management
ADAR1 Capital Management is an Austin-based investment manager focused on public and private equity investments in life sciences and biotechnology. Public adviser and investor materials point to a specialist healthcare and biotech orientation. ADAR1's relevance to psychedelic medicine is source-backed through atai's 2025 private placement. The record is useful for mapping public-market and crossover healthcare capital around psychedelic mental-health drug development.
View Profile
Investor Category
Institutional Investors
HQ
HQ: United States
Public MarketsGrowth / Late StageNonprofit / grant-backed
Company-Led Drug Development & Commercialization
Portfolio Signals
atai Life Sciences
Private placement financing · approximately $50 million · Jul 1, 2025
AtaiBeckley
Portfolio stakeholder
Aja Ventures
Aja Ventures is a Canadian investment company associated with venture investing in plant medicine, technology, and wellness, with a stated emphasis on early-stage ventures developing psychedelic medicine. Public-facing profiles also describe it as a venture capital fund or investment company connected to psychedelic-adjacent healthcare and longevity themes. It matters in the psychedelic ecosystem because its stated strategy includes backing early-stage psychedelic therapy and drug-discovery efforts, alongside related areas like genetic testing, functional medicine, and personalized healthcare. Public profile sources also point to investments or strategic exposure in companies tied to natural psychedelic medicines and plant-based wellness.
View Profile
Investor Category
Venture Capital
HQ
HQ: Canada
SeedSeries A/BGrowth / Late Stage
Portfolio Signals
Filament Ventures
Cellular Goods
Seed · undisclosed · Mar 1, 2021
Ally Bridge Group
Ally Bridge Group is a global healthcare investment management firm investing across private and public life-science markets. Its website emphasizes cross-market healthcare investing, with teams and offices spanning New York and Hong Kong. Within psychedelic medicine, Ally Bridge is relevant through atai's 2025 private placement. This makes it a healthcare crossover investor in the sector, not a dedicated psychedelic investor.
View Profile
Investor Category
Institutional Investors
HQ
HQ: United States
Growth / Late StagePublic MarketsMulti-StageNonprofit / grant-backed
Company-Led Drug Development & Commercialization
Portfolio Signals
atai Life Sciences
Private placement financing · approximately $50 million · Jul 1, 2025
AtaiBeckley
Portfolio stakeholder
Ambria Capital
Ambria Capital is a venture capital firm that focuses on early-stage companies in mental health and technology, with a stated current emphasis on psychedelic therapies and technologies. The firm says it invests its own money and can fund companies at any stage and in any amount, and its leadership includes founder Michael Sobeck and managing partner Cody Shandraw. The firm matters in the psychedelic ecosystem because it explicitly backs psychedelic therapies and technologies and describes itself as one of the more active investors in the space. Its website and related public materials point to investments and support across the industry, including companies such as Wesana Health, and it has also been associated with broader neurowellness and brain-health investing through Phyto Partners.
View Profile
Investor Category
Venture Capital
HQ
HQ: United States
SeedSeries A/BGrowth / Late Stage
Portfolio Signals
Public portfolio context is limited.
Apeiron Investment Group
Apeiron Investment Group is a discretionary investment firm founded and owned by Christian Angermayer. Its website says it manages approximately $7 billion and operates with teams in New York, London, Berlin, Abu Dhabi, and Malta, with a primary focus on the U.S. market. It matters in the psychedelic ecosystem because Apeiron has been a recurring backer of atai Life Sciences, including co-leading atai's $125 million Series C financing in 2020 and its $50 million private placement financing in 2025. Apeiron's own website also describes psychedelics as a key part of its investment story and says it has been instrumental in the renaissance of psychedelics as treatments for mental health issues.
View Profile
Investor Category
Venture Capital
HQ
HQ: United Arab Emirates
SeedSeries A/BGrowth / Late Stage
Portfolio Signals
atai Life Sciences
Private placement financing (co-led) · $50m financing · Jul 1, 2025
Apollo Projects
Apollo Projects is a venture platform associated with moonshot-style company building and early investments. Public sources describe it as a vehicle launched by the Altman brothers in 2020, with a broad mandate rather than a psychedelic-specific strategy. Its relevance to psychedelic medicine comes from Journey Colab, where Apollo Projects appears in launch and Series A financing evidence. The record should be treated as moderate-confidence broad venture capital with a verified Journey Colab connection.
View Profile
Investor Category
Venture Capital
HQ
HQ: United States
Pre-SeedSeedSeries A/B
Company-Led Drug Development & Commercialization
Portfolio Signals
Journey Colab
Initial investment · $3 million · Oct 26, 2020
Ark Invest
ARK Invest, legally ARK Investment Management LLC, is an active investment manager founded by Cathie Wood in 2014. It is based in New York, United States, and focuses on disruptive innovation across public markets, with some private-market exposure through ARK Venture Fund. ARK has published dedicated research on psychedelic therapeutics and the field’s clinical and commercial potential. Its public research and thematic investment approach make it a relevant institutional stakeholder for psychedelic drug development companies, especially those advancing novel therapies into clinical and public-market stages.
View Profile
Investor Category
Institutional Investors
HQ
HQ: United States
Growth / Late StagePublic MarketsMulti-StageNonprofit / grant-backed
Portfolio Signals
Public portfolio context is limited.
ARTIS Ventures
ARTIS Ventures is a San Francisco venture capital firm focused on frontier technologies at the intersection of life science, health, and advanced computing. Its current public language emphasizes resilience, TechBio, and backing companies that reshape human health and related systems. ARTIS is a strong psychedelic-adjacent investor record because it has direct exposure to Delix Therapeutics and publicly hosts Delix within its portfolio. It should be described as a techbio and healthcare VC with a source-backed neuroplastogen investment, not as a dedicated psychedelic investor.
View Profile
Investor Category
Venture Capital
HQ
HQ: United States
SeedSeries A/B
Company-Led Drug Development & Commercialization
Portfolio Signals
Delix Therapeutics
Series A · $70 million · Sep 27, 2021
AtaiBeckley
AtaiBeckley Inc. is a clinical-stage biotechnology company formed in 2025 through the strategic combination of atai Life Sciences and Beckley Psytech. It operates as a public company focused on developing rapid-acting, durable, and convenient mental health treatments, with a strong psychedelic-therapeutics emphasis. Its principal executive office is in New York, New York, United States. AtaiBeckley matters in the psychedelic ecosystem because it combines clinical development capabilities with a public-market platform that can support late-stage psychedelic drug programs. Public disclosures describe pipeline work that includes BPL-003 and note that the company’s psychedelic-based therapies are being advanced through the Beckley Psytech strategic investment and later combination.
View Profile
HQ
HQ: United States
Series A/BGrowth / Late StageMulti-StageNonprofit / grant-backed
Company-Led Drug Development & Commercialization
Portfolio Signals
Beckley Psytech
Strategic investment and collaboration · $50m total investment ($40m primary + $10m secondary) · Jan 4, 2024
Berenberg
Berenberg, legally Berenberg, Gossler & Co., is a long-established private bank and financial services group founded in 1590 in Hamburg. It operates across investment banking, asset management, corporate banking, and wealth management, and describes itself as one of Europe’s leading private banks. In the psychedelic ecosystem, Berenberg matters mainly as a public-markets and healthcare-capital-markets participant rather than a dedicated psychedelic specialist. Its published equity and healthcare strategies focus on growth-oriented companies, and its investment banking business has supported multiple life sciences and biotech financings, including healthcare-sector equity transactions.
View Profile
Investor Category
Institutional Investors
HQ
HQ: Germany
Growth / Late StagePublic MarketsMulti-StageNonprofit / grant-backed
Portfolio Signals
Public portfolio context is limited.
Bicycle Day Ventures
Bicycle Day Ventures is a psychedelic-focused angel syndicate associated with Chris Kantrowitz. AngelList materials describe a syndicate thesis around psychedelic medicine and related industries, with visible portfolio exposure to companies including Beckley Psytech and Quantified Citizen. The syndicate remains a useful early-stage investor record because it is explicitly focused on psychedelic medicine, but its public identity fields are lighter than those of institutional funds. Public copy should stay precise about the syndicate structure and avoid overstating firm scale or office details.
View Profile
Investor Category
Angel Investors
HQ
HQ: United States
Pre-SeedSeed
Real-World Data & Evidence Collection
Portfolio Signals
Beckley Psytech
Series B · $80 million · Aug 16, 2021
Quantified Citizen
Seed VC · undisclosed · Mar 17, 2022
Blackhawk Growth Corp
Blackhawk Growth Corp. is a publicly traded Canadian investment holding company / investment issuer that invests in equity and debt instruments of companies to generate shareholder returns. Public filings and exchange listings place the company in Vancouver, British Columbia, Canada, while the company itself has also described its strategy as active support for portfolio companies in North America. It matters in the psychedelic ecosystem because Blackhawk has publicly backed psychedelic-related drug development, including MindBio Therapeutics, which it described as a clinical-stage company pioneering psychedelic microdosing research. That makes Blackhawk a relevant crossover investor in the adjacent cannabis, mental health, and psychedelic therapeutics landscape rather than a pure-play life sciences fund.
View Profile
Investor Category
Venture Capital
HQ
HQ: Canada
SeedSeries A/BGrowth / Late StageNonprofit / grant-backed
Company-Led Drug Development & Commercialization
Portfolio Signals
MindBio Therapeutics
private investment · Aug 31, 2021
BlackRock
BlackRock is a global asset manager and fiduciary investor founded in 1988 in New York. Its investment stewardship business engages with public companies and votes on behalf of clients across index and active portfolios. Public BlackRock location pages list its New York office at 50 Hudson Yards, New York, NY 10001, United States. In the psychedelic ecosystem, BlackRock is relevant primarily as a large public-markets stakeholder rather than a dedicated psychedelic specialist. Its stewardship and portfolio activities span global public companies and multiple asset classes, so it may appear as a shareholder in listed life sciences or healthcare names even though it does not advertise a public psychedelic focus.
View Profile
Investor Category
Institutional Investors
HQ
HQ: United States
Growth / Late StagePublic MarketsMulti-StageNonprofit / grant-backed
Portfolio Signals
Public portfolio context is limited.
Boxer Capital
Boxer Capital is a biotechnology investment firm and private investment fund based in San Diego, California. Its public materials describe it as a full life cycle investor focused on fundamental, research-based investing across private and public markets, with activity spanning early-stage through late-stage biotech. It matters to the psychedelic ecosystem because its investing style overlaps with the kinds of capital needed by drug-development companies, including crossover, private, and public-market financing. Boxer Capital’s public disclosures emphasize investing across the drug development lifecycle and supporting therapeutics companies from company formation through late-stage development, which can make it relevant to psychedelic medicine companies even when they are not explicitly psychedelic-focused.
View Profile
Investor Category
Venture Capital
HQ
HQ: United States
SeedSeries A/BGrowth / Late Stage
Company-Led Drug Development & CommercializationEducational Platforms & Resources
Portfolio Signals
GH Research
Series B · undisclosed · Apr 1, 2021
Cybin
registered direct offering · undisclosed · Jun 1, 2025
BTIG
BTIG is a global financial services firm that provides institutional sales and trading, research, and investment banking services. Its website describes the firm as serving institutional and corporate clients across public markets, with a strong healthcare banking presence. The firm’s New York office at 65 East 55th Street is the address most prominently listed on BTIG’s site. In the psychedelic ecosystem, BTIG is relevant primarily as a healthcare and capital markets intermediary rather than a dedicated psychedelic investor. BTIG’s healthcare investment banking coverage includes biotechnology and pharmaceuticals, which can overlap with psychedelic drug-development companies if they seek public-market financing, strategic advice, or aftermarket support.
View Profile
Investor Category
Institutional Investors
HQ
HQ: United States
Growth / Late StagePublic MarketsMulti-StageNonprofit / grant-backed
Portfolio Signals
Public portfolio context is limited.
BVF Partners
BVF Partners L.P. is a private investment manager based in San Francisco, California. Public filings and market data describe it as an SEC-registered investment adviser and biotechnology-focused investor, rather than a broad consumer or software venture fund. In the psychedelic ecosystem, BVF Partners matters mainly as a healthcare and drug-development capital provider whose investment style aligns more with life sciences than with lifestyle psychedelics. Publicly available sources point to biotech as its core theme, which makes it potentially relevant to companies developing regulated therapeutic compounds and clinical-stage programs.
View Profile
Investor Category
Venture Capital
HQ
HQ: United States
SeedSeries A/BGrowth / Late Stage
Portfolio Signals
Public portfolio context is limited.
Canaccord Genuity
Canaccord Genuity Group Inc. is a global independent investment dealer with capital markets and wealth management operations, including investment banking and advisory services for public and private companies. Public company filings identify its head office in Vancouver, British Columbia, Canada. In the psychedelic ecosystem, Canaccord Genuity is relevant mainly as a capital-markets adviser rather than a dedicated psychedelic specialist. Its published transactions show activity in adjacent areas such as cannabis, healthcare, and public growth financings, which can intersect with psychedelic companies that access public markets or pursue strategic capital raises.
View Profile
Investor Category
Institutional Investors
HQ
HQ: Canada
Growth / Late StagePublic MarketsMulti-StageNonprofit / grant-backed
Portfolio Signals
Public portfolio context is limited.
Cantor Fitzgerald
Cantor Fitzgerald is a global financial services firm founded in 1945 that provides investment banking, capital markets, fixed income, equities, prime services, research, asset management, and related services. Its website identifies it as a privately owned firm with a broad institutional and public-markets orientation, and its headquarters is in New York, New York, United States. For the psychedelic ecosystem, Cantor Fitzgerald appears relevant mainly as a capital-markets and financing intermediary rather than a dedicated psychedelic investor. Public materials show activity in investment banking, SPACs, PIPE placements, and asset management, which can make it relevant to public psychedelic companies seeking listings, financings, or coverage, but there is no public evidence of a specific psychedelic focus.
View Profile
Investor Category
Institutional Investors
HQ
HQ: United States
Growth / Late StagePublic MarketsMulti-StageNonprofit / grant-backed
Portfolio Signals
Public portfolio context is limited.
Catalio Capital Management
Catalio Capital Management is a New York-based healthcare investment firm that invests across private, public, and credit markets. Its public materials emphasize innovative healthcare companies across the company lifecycle, with a strong orientation toward biomedical technology. Catalio belongs in the psychedelic ecosystem as a healthcare-specialist investor with atai-related investments and a historical COMPASS Pathways connection through Camden Partners Nexus. It should be read as a life-science investor with repeated source-backed sector exposure, not as a dedicated psychedelic fund.
View Profile
Investor Category
Venture Capital
HQ
HQ: United States
Multi-Stage
Company-Led Drug Development & CommercializationEducational Platforms & Resources
Portfolio Signals
atai Life Sciences
Series C · $125 million · Nov 23, 2020
COMPASS Pathways
Series B · $80m · Apr 27, 2020
Cowen
Cowen is a U.S.-based diversified financial services firm and institutional investor platform that has historically combined investment banking, research, sales and trading, prime brokerage, and investment management. Public filings describe Cowen as founded in 1918 and headquartered in New York, with principal executive offices at 599 Lexington Avenue in New York City. In the psychedelic ecosystem, Cowen matters mainly as a broad healthcare capital provider rather than a dedicated psychedelic investor. Its public investment management strategies have included healthcare royalties, private healthcare investing, and public and private healthcare strategies, which can place it near adjacent biotech and neuroscience opportunities even though no public psychedelic focus is stated.
View Profile
Investor Category
Institutional Investors
HQ
HQ: United States
Growth / Late StagePublic MarketsMulti-StageNonprofit / grant-backed
Portfolio Signals
Public portfolio context is limited.
Deerfield
Deerfield Management Company is a healthcare investment firm launched in 1994. Its public materials describe it as an investor across therapeutics, medical devices, diagnostics, digital health, and healthcare services, investing across the capital structure and at all stages of company development. Deerfield’s contact page lists its New York City office at 345 Park Avenue South in New York, New York, United States. Deerfield is relevant to the psychedelic ecosystem primarily through its broad therapeutics focus and its ability to back early-stage to later-stage life science companies. While its public website does not identify a dedicated psychedelic program, its investment platform includes drug-development-oriented work and a portfolio spanning early-stage therapeutics, which makes it a plausible investor in adjacent mental-health and neurotherapeutics opportunities.
View Profile
Investor Category
Venture Capital
HQ
HQ: United States
SeedSeries A/BGrowth / Late Stage
Portfolio Signals
Public portfolio context is limited.
EF Hutton
EF Hutton is a global full-service investment bank focused on middle-market and emerging growth companies, with public and private offerings across debt and equity capital markets. Its website lists product offerings including investment banking and advisory, private credit, asset-backed finance, credit tenant lease and ground lease finance, private equity, and project and infrastructure finance. Public materials describe the firm as headquartered in New York, New York. In the psychedelic ecosystem, EF Hutton is relevant primarily as a capital markets and research intermediary rather than as a dedicated psychedelic specialist. Public materials show the firm has provided sell-side research on small and mid-cap companies and has covered or advised companies in the broader mental health and biotech space, which can overlap with public psychedelic issuers, but its public positioning remains industry-agnostic rather than explicitly psychedelic-focused.
View Profile
Investor Category
Institutional Investors
HQ
HQ: United States
Growth / Late StagePublic MarketsMulti-StageNonprofit / grant-backed
Portfolio Signals
EF Hutton Acquisition Corporation I
SPAC IPO · $115,000,000 · Sep 1, 2022
Empath Ventures
Empath Ventures is a venture capital firm focused on psychedelic medicine and related therapeutic approaches. Public profiles place the firm in Los Angeles, California, United States, and describe it as an early-stage investor with activity across seed and Series A stages, with some sources also indicating broader stage coverage. The firm is relevant to the psychedelic ecosystem because it has publicly positioned itself around psychedelic medicine companies and adjacent health technologies. Public references also connect Empath Ventures to companies and themes in psychedelic medicine, neurotechnology, and novel therapeutics.
View Profile
Investor Category
Venture Capital
HQ
HQ: United States
SeedSeries A/BGrowth / Late Stage
Media & CommunicationTechnology, Data, & Software Platforms
Portfolio Signals
Wavepaths
Seed · $4.5M · Nov 1, 2021
Evercore
Evercore is a publicly traded global independent investment banking advisory firm, not a venture fund or direct psychedelic investor. It was founded in 1995 and is headquartered in New York, United States, with offices and affiliate offices across major financial centers in North America, Europe, the Middle East, and Asia. In the psychedelic ecosystem, Evercore’s relevance is mainly as a capital markets and strategic advisory firm rather than a specialist life-sciences investor. Its healthcare and biotech coverage, private capital markets, and public-company advisory work can make it relevant to psychedelic companies seeking M&A advice, financing, or public-market transactions.
View Profile
Investor Category
Institutional Investors
HQ
HQ: United States
Growth / Late StagePublic MarketsMulti-StageNonprofit / grant-backed
Portfolio Signals
Public portfolio context is limited.
Evolve Ventures
Evolve Ventures is the venture arm of EVOLVE, an umbrella organization that says it has two divisions: Evolve Ventures and Evolve Foundation. The firm says Evolve Ventures was initially funded by the Shao family with a $100 million pool and invests in for-profit companies aligned with its mission. The organization describes its work as global, with a particular focus on the United States and China. Evolve Ventures appears in the psychedelic ecosystem through its investments in companies such as Beckley Waves, Homecoming, and MycoMedica on its public investments page. Its portfolio also includes mental health, meditation, and consciousness-oriented companies, which places it near the broader psychedelic-adjacent landscape even when the company itself is not a direct drug-developer.
View Profile
Investor Category
Venture Capital
HQ
Not listed
SeedSeries A/BGrowth / Late Stage
Portfolio Signals
Beckley Waves
program-related investment
Homecoming
venture investment
Ferring Ventures
Ferring Ventures is an investment vehicle associated with Ferring's broader life-science and biopharmaceutical platform in Switzerland. Public and registry materials tie the entity to St-Prex and place it within a larger organization focused on therapeutic innovation and commercialization. Ferring Ventures matters for psychedelic coverage because it shows strategic corporate capital entering the space through atai-linked financings in 2025. That makes it more relevant than a passive one-off holder, while still leaving it outside the category of dedicated psychedelic investors.
View Profile
HQ
HQ: Switzerland
Growth / Late StageMulti-Stage
Company-Led Drug Development & Commercialization
Portfolio Signals
AtaiBeckley
Concurrent private placement · $30.0M · Jun 2, 2025
atai Life Sciences
Private placement financing · approximately $50 million · Jul 1, 2025
Founders Fund
Founders Fund is a generalist venture capital firm known for backing large, category-defining technology companies across sectors. Its public positioning is broad rather than healthcare-specific, and the firm is not publicly organized around psychedelic medicine. Its relevance to psychedelic medicine comes from participation in COMPASS Pathways' 2020 Series B round. That makes Founders Fund a meaningful crossover investor in a landmark psilocybin drug developer, but not a dedicated psychedelic investor.
View Profile
Investor Category
Venture Capital
HQ
HQ: United States
Multi-Stage
Company-Led Drug Development & CommercializationEducational Platforms & Resources
Portfolio Signals
COMPASS Pathways
Series B · $80m · Apr 27, 2020
Future Ventures
Future Ventures is a venture capital firm co-founded by Steve Jurvetson and Maryanna Saenko. The firm says it focuses on seed and early-stage investments in founder-led, mission-driven companies and describes itself as based in Pacifica, California through Saenko’s public bio and the firm’s Bay Area footprint. Future Ventures matters in the psychedelic ecosystem because it has backed and publicly listed atai Life Sciences and Osmind, both adjacent to mental health and psychedelic medicine infrastructure. Its public materials also emphasize biology, therapeutics, and frontier technology, which aligns with the broader ecosystem around drug development and digital care platforms.
View Profile
Investor Category
Venture Capital
HQ
HQ: United States
SeedSeries A/BGrowth / Late Stage
Portfolio Signals
atai Life Sciences
private investment
Gaingels
Gaingels is a venture investment syndicate and network that co-invests with venture capital leads across a wide range of sectors and stages, from pre-seed to pre-IPO. Its public materials describe it as an LGBTQIA+/allies investor network focused on diversity, inclusion, and access in venture. The organization’s mailing address is in New York, New York, United States. Gaingels says it invests globally and supports venture-backed companies in any sector, with a notable emphasis on healthcare and biotech alongside other high-growth categories. In the psychedelic ecosystem, that makes it relevant as a potential co-investor for drug-development companies that fit its broader mental health and biotech orientation, even though its public portfolio page does not single out psychedelics as a dedicated focus.
View Profile
Investor Category
Angel Investors
HQ
HQ: United States
Pre-SeedSeed
Portfolio Signals
Public portfolio context is limited.
H.C. Wainwright & Co.
H.C. Wainwright & Co., LLC is a New York-based full-service investment bank offering investment banking, equity research, sales and trading, strategic advisory, and corporate access services. The firm says it serves public and private growth companies across multiple sectors and regions, and its office is at 430 Park Avenue, New York, New York 10022. In the psychedelic ecosystem, H.C. Wainwright matters primarily as a capital-markets and conference platform rather than as a dedicated psychedelic specialist. Its public materials show a strong life sciences and biotechnology orientation, and its events have included companies such as Awakn Life Sciences and Cybin in the broader psychedelics space.
View Profile
Investor Category
Institutional Investors
HQ
HQ: United States
Growth / Late StagePublic MarketsMulti-StageNonprofit / grant-backed
Portfolio Signals
Public portfolio context is limited.
Hercules Capital
Hercules Capital, Inc. is a publicly traded specialty finance company and business development company focused on senior secured venture growth loans for venture capital-backed companies. It was founded in 2003 and is based in San Mateo, California, in the United States. Hercules is relevant to the psychedelic ecosystem because its life sciences practice finances biotechnology and other healthcare companies at clinical and commercial stages, including companies in the broader CNS and drug development space. Public filings show Hercules has been a lender to ATAI Life Sciences, making it a financing counterpart to a psychedelics-focused public company.
View Profile
Investor Category
Venture Capital
HQ
HQ: United States
SeedSeries A/BGrowth / Late StageNonprofit / grant-backed
Portfolio Signals
atai Life Sciences
private placement · Jan 1, 2025
Iter Investments
Iter Investments is a venture capital firm focused on emerging companies developing alternative therapeutics for behavioral and mental health, with a stated emphasis on the psychedelic ecosystem. The firm’s public materials describe it as a Florida-based investor, with headquarters in South Florida. Iter matters in the psychedelic ecosystem because it backs companies across the sector’s value chain, including drug development, clinics, digital platforms, and supporting infrastructure. Its public portfolio includes Psygen, Awakn Life Sciences, Wesana, PsyTech, and Nucleus-related ecosystem assets, showing a broad strategy beyond a single therapeutic modality.
View Profile
Investor Category
Venture Capital
HQ
HQ: United States
Pre-SeedSeedSeries A/B
Company-Led Drug Development & CommercializationPharmaceutical Manufacturing
Portfolio Signals
Psygen
Portfolio investment
Awakn Life Sciences
Portfolio investment
Jefferies
Jefferies is a global full-service investment banking and capital markets firm, rather than a specialist psychedelic investor. Its public materials describe the firm as operating worldwide, with principal offices in New York and regional headquarters in London and Hong Kong. In the psychedelic ecosystem, Jefferies matters mainly as a broad capital-markets and research platform that has published industry thought leadership on psychedelics and mental health. Its public primer on mental health and psychedelics notes active investor interest in the space and discusses public and private psychedelic drug-development companies, but it does not establish Jefferies as a dedicated psychedelic-focused fund.
View Profile
Investor Category
Institutional Investors
HQ
HQ: United States
Growth / Late StagePublic MarketsMulti-StageNonprofit / grant-backed
Portfolio Signals
Public portfolio context is limited.
JLS Fund
JLS Fund is a venture capital fund focused on neuroscience and psychedelic medicine. Its website says the firm was founded in 2019 and lists a New York office at 40 Sutton Place, New York, USA. The fund is active across the psychedelic ecosystem through investments and advisories in companies such as Enthea, Psilera, TRIPP, Gilgamesh, and ProNovo Therapeutics. It also publishes regular industry commentary on psychedelics and neuroscience, which helps position it as a visible specialist investor in the sector.
View Profile
Investor Category
Venture Capital
HQ
HQ: United States
SeedSeries A/BGrowth / Late Stage
Company-Led Drug Development & Commercialization
Portfolio Signals
Enthea
Fund investment
Psilera
Fund investment
Johnson & Johnson
Johnson & Johnson is a publicly traded global healthcare company rather than a venture fund or dedicated asset manager. Its business spans pharmaceuticals and medical technology, and the company is based in New Brunswick, New Jersey, United States. In the psychedelic ecosystem, Johnson & Johnson matters mainly through its neuroscience and psychiatry-adjacent pharmaceutical activity rather than as a standalone investor. Its acquisition of Intra-Cellular Therapies, a CNS-focused biopharma, shows continued interest in neuropsychiatric therapeutics and related clinical-stage assets.
View Profile
Investor Category
Institutional Investors
HQ
HQ: United States
Growth / Late StagePublic MarketsMulti-StageNonprofit / grant-backed
Academic & Non-Profit Research
Portfolio Signals
Public portfolio context is limited.
Kevin O'Leary
Kevin O'Leary is a Canadian entrepreneur and investor best known for his television role on Shark Tank and for building an investor brand around startups and private-market deals. His official site presents him as actively looking for new business proposals, and third-party profiles place him in Toronto, Ontario, Canada, while his public investor activity is global. In the psychedelic ecosystem, O'Leary is notable as an early investor and public advocate for MindMed, a psychedelic-focused drug-development company. Public interviews describe his interest as centered on regulated pharmaceutical development and binary, long-duration biotech-style outcomes rather than recreational use.
View Profile
Investor Category
Angel Investors
HQ
HQ: Canada
SeedSeries A/B
Portfolio Signals
MindMed
Seed · undisclosed · Jan 1, 2020
Leafy Tunnel
Leafy Tunnel is a venture capital firm focused on alternative medicine, with an emphasis on medicinal cannabis and psychedelics. Its public-facing materials describe it as an early-stage investor and place its headquarters in London, United Kingdom. In the psychedelic ecosystem, Leafy Tunnel matters because it has publicly positioned itself around medical cannabis and global medical psychedelics opportunities, with a stated focus on Seed and Series A investing. Public funding coverage shows it led Lyphe Group’s £5m Series A round in 2022, supporting expansion across Europe.
View Profile
Investor Category
Venture Capital
HQ
HQ: United Kingdom
SeedSeries A/BGrowth / Late StageNonprofit / grant-backed
Portfolio Signals
Public portfolio context is limited.
Levitee Labs
Levitee Labs Inc. is a British Columbia company that was incorporated on January 23, 2019 and later became listed on the Canadian Securities Exchange under the symbol LVT. Public filings describe it as an integrative wellness company with activities aimed at alternative medicine and the broader psychedelic industry. The company’s public disclosures frame its role around acquiring and building wellness assets complementary to the evolving psychedelic sector, including clinics, pharmacies, nutraceuticals, and other adjacent healthcare businesses. That makes Levitee Labs relevant as an operator and capital allocator around psychedelic-adjacent healthcare infrastructure rather than a traditional early-stage venture fund.
View Profile
Investor Category
Venture Capital
HQ
HQ: Canada
SeedSeries A/BGrowth / Late Stage
Clinical Care Delivery Organizations
Portfolio Signals
Public portfolio context is limited.
Matt Mullenweg
Matt Mullenweg is the co-founder and CEO of Automattic, the company behind WordPress.com, WooCommerce, Jetpack, and Tumblr, and he also describes Audrey Capital as an angel investment and research company. Public sources characterize him as an angel investor with a strong preference for open-source-oriented companies and early-stage startups. His relevance to the psychedelic ecosystem is indirect rather than thematic: available public materials do not show a specific psychedelic investment thesis or public psychedelic portfolio. He is still a useful investor to track in adjacent infrastructure and software circles because his investment activity is centered on early-stage, open-source-friendly businesses, not life sciences or psychedelic drug development.
View Profile
Investor Category
Angel Investors
HQ
HQ: United States
SeedSeries A/B
Foundations & Philanthropy
Portfolio Signals
Public portfolio context is limited.
Maxim Group
Maxim Group LLC is a New York-based full-service investment bank, securities firm, and wealth management platform that provides investment banking, capital markets, research, sales and trading, and private wealth services. Public sources list its headquarters in New York, NY, with offices in Florida, New Jersey, and Connecticut. In the psychedelic ecosystem, Maxim Group matters primarily as a Wall Street coverage and capital-markets participant rather than as a dedicated psychedelic investor. Its research platform has covered multiple psychedelic-focused public companies, and its investment-banking business also works across healthcare and biotechnology, which places it near the financing activity around the sector.
View Profile
Investor Category
Institutional Investors
HQ
HQ: United States
Growth / Late StagePublic MarketsMulti-StageNonprofit / grant-backed
Portfolio Signals
Public portfolio context is limited.
MBX Capital
MBX Capital is an early-stage venture capital firm focused on deep health companies, with an official FAQ stating it is agnostic to sector so long as the company has a clear deep health vision. The firm says it typically invests in companies’ first or second institutional rounds and can also participate in later-stage financings. Its public mailing address is in Claymont, Delaware, United States. In the psychedelic ecosystem, MBX Capital is relevant because its portfolio page includes Journey Colab, described as building psychedelic therapies for addiction, alongside other mental-health and neuro-related companies. That makes MBX Capital a broader deep-health investor with at least one public psychedelic-adjacent portfolio company and a stated willingness to invest globally when the opportunity fits.
View Profile
Investor Category
Venture Capital
HQ
HQ: United States
SeedSeries A/BGrowth / Late Stage
Company-Led Drug Development & Commercialization
Portfolio Signals
Journey Colab
Partnered · Jan 1, 2021
Mike Novogratz
Mike Novogratz is an American investor and the founder and CEO of Galaxy, where he leads a global digital-assets and blockchain-focused investment platform. Public company filings list his principal business address in New York City, and Galaxy’s headquarters is also reported as New York City. He matters to the psychedelic ecosystem mainly as a public backer of psychedelic biopharma through atai Life Sciences, where investor lists and commentary name him among notable investors. Public references also link Novogratz to the broader psychedelic investment network alongside other prominent financiers involved in drug-development and mental-health innovation.
View Profile
Investor Category
Angel Investors
HQ
HQ: United States
SeedSeries A/B
Portfolio Signals
atai Life Sciences
private placement · undisclosed · Aug 1, 2019
Mission Club
Mission Club is an angel investor community and education platform. Public materials describe it as supporting the psychedelic ecosystem and related startups, with a focus on early-stage investing. The organization appears to be based in Toronto, Canada, based on a public event listing and a Canadian corporate registration record for a Mission Club entity. It has public ties to psychedelic community-building and investor programming rather than a large institutional fund structure.
View Profile
Investor Category
Angel Investors
HQ
HQ: Canada
SeedSeries A/B
Portfolio Signals
Public portfolio context is limited.
Morgan Stanley
Morgan Stanley is a global financial services firm and institutional investor founded in 1935. Public Morgan Stanley pages describe the firm as headquartered in New York, with worldwide offices and clients across institutions, corporations, governments, and individuals. In the psychedelic ecosystem, Morgan Stanley’s relevance is mostly indirect: its investment management arm covers global public and private markets, and its published research has discussed psychedelics as an emerging theme in healthcare and investing. The firm does not present a public psychedelic investment focus, but its broad capital-markets and growth-investing platform could make it relevant to late-stage life sciences and adjacent healthcare companies.
View Profile
Investor Category
Institutional Investors
HQ
HQ: United States
Growth / Late StagePublic MarketsMulti-StageNonprofit / grant-backed
Portfolio Signals
Public portfolio context is limited.
Negev Capital
Negev Capital is a venture capital fund focused on CNS and brain-health therapeutics, with a stated strategy centered on seed to Series A investments. The fund says it is domiciled in the Cayman Islands and that key team members are based in Limassol, Cyprus, Vienna, and New York. It matters in the psychedelic ecosystem because Negev Capital has backed and exited multiple companies in psychedelic-derived and neuropsychiatric drug development, including Gilgamesh Pharmaceuticals, Mindset Pharma, Bright Minds Biosciences, and others. The fund describes its thesis as supporting psychedelic-derived and novel neuropsychiatric compounds that can mature into mainstream therapeutic categories.
View Profile
Investor Category
Venture Capital
HQ
HQ: Cayman Islands
SeedSeries A/BGrowth / Late Stage
Academic & Non-Profit Research
Portfolio Signals
Small Pharma Ltd
follow-on / strategic investment · USD 1 million cumulative · Sep 21, 2021
Neo Kuma
Neo Kuma Ventures LLP is a London-based venture capital investor focused on psychedelic healthcare and adjacent drug-development opportunities. Public materials describe it as investing in early-stage psychedelic healthcare companies, with a global market scope and a European tilt. The firm is relevant to the psychedelic ecosystem because it has backed several of the sector’s best-known companies and positions itself around clinical research, therapeutics, and regulated healthcare delivery. Public profiles and coverage identify portfolio exposure to companies such as Atai Life Sciences, Beckley Psytech, and Bright Minds Biosciences.
View Profile
Investor Category
Venture Capital
HQ
HQ: United Kingdom
SeedSeries A/BGrowth / Late Stage
Company-Led Drug Development & Commercialization
Portfolio Signals
atai Life Sciences
Series C · undisclosed · Nov 1, 2020
Bright Minds Biosciences
undisclosed
Noetic Fund
Noetic Fund is a Toronto-based venture firm investing in early-stage technologies focused on mental health and wellbeing. Its public materials describe a diversified strategy across novel drug therapeutics, psychedelic-assisted therapies, digital health, medical devices, wearables, and other evidence-backed solutions, with a global outlook and emphasis on early intervention and prevention. The firm is explicitly tied to the psychedelic medicine ecosystem through its own fund announcements, reading list, and portfolio disclosures. Publicly named investments include CaaMTech, the Alexander Shulgin Research Institute, and Damona Pharmaceuticals, which positions Noetic as an active capital provider in psychedelic drug development and adjacent mental health innovation.
View Profile
Investor Category
Social-Impact Investors
HQ
HQ: Canada
SeedSeries A/BMulti-StageNonprofit / grant-backed
Company-Led Drug Development & Commercialization
Portfolio Signals
CaaMTech
Series A financing · $22m Series A · Sep 15, 2022
Alexander Shulgin Research Institute
Series A financing · $8m+ Series A · Dec 20, 2022
OMX Venture
OMX Ventures is a venture capital firm based in Chicago, Illinois, focused on bioengineering and life sciences investing. Its public materials describe a technology-first approach centered on early-stage companies working across biology, big data, AI, therapeutics, bio tools, diagnostics, and synthetic biology. In the psychedelic ecosystem, OMX matters because it is a founding investor in Delix Therapeutics, a company developing non-hallucinogenic versions of psychedelic compounds for psychiatric and neurological indications. OMX has also publicly participated in other drug-development and biotech rounds, suggesting a broader interest in therapeutics that overlap with psychedelic-adjacent neuroscience.
View Profile
Investor Category
Venture Capital
HQ
HQ: United States
SeedSeries A/BGrowth / Late Stage
Company-Led Drug Development & Commercialization
Portfolio Signals
Delix Therapeutics
Series A · $70 million · Sep 27, 2021
Oppenheimer
Oppenheimer & Co. Inc. is a global financial institution offering wealth management, capital markets, and investment banking services. Its institutional-facing businesses include equity research, investment banking, and institutional services, and its principal place of business is in New York, New York. In the psychedelic ecosystem, Oppenheimer matters primarily as a generalist capital-markets and healthcare finance platform rather than a specialist psychedelic investor. Its healthcare research and investment banking coverage spans biotechnology, biopharmaceuticals, specialty pharmaceuticals, and emerging-growth companies, which can make it relevant to public and private life-sciences issuers that overlap with psychedelic drug development.
View Profile
Investor Category
Institutional Investors
HQ
HQ: United States
Growth / Late StagePublic MarketsMulti-StageNonprofit / grant-backed
Portfolio Signals
Public portfolio context is limited.
Orbimed Advisors
OrbiMed Advisors is a global healthcare investment manager that invests across the life sciences and healthcare sectors, from seed-stage private companies to large publicly traded companies. Its platform spans public equity, private equity, and private credit/royalty strategies, and the firm says its investment business was founded in New York City in 1989. For the psychedelic ecosystem, OrbiMed matters mainly as a large, healthcare-focused capital provider rather than as a specialist psychedelic backer. Its public materials describe broad investing across biopharmaceuticals, medical devices, diagnostics, and healthcare services, with capital deployed across the full company lifecycle and capital structure, which makes it relevant to psychedelic companies only where they fit broader drug development or healthcare themes.
View Profile
Investor Category
Institutional Investors
HQ
HQ: United States
Growth / Late StagePublic MarketsMulti-StageNonprofit / grant-backed
Portfolio Signals
Public portfolio context is limited.
Origin Therapeutics
Origin Therapeutics Holdings Inc. is a publicly listed, actively managed investment issuer focused on equity investments in psychedelics-related companies. Public company materials place it in Vancouver, British Columbia, which strongly suggests a Canadian base. The firm is positioned as a sector investor rather than an operating biotech, with a mandate to provide investors diversified exposure to private psychedelics companies. Its public materials and announcements show an emphasis on early-stage and growth-oriented psychedelic businesses, especially drug development. Origin Therapeutics appears to function as a specialized capital provider in the psychedelic ecosystem, with portfolio updates centered on companies developing psilocybin-based therapies. That makes it relevant as a financing vehicle and visibility source for emerging psychedelic drug programs.
View Profile
Investor Category
Venture Capital
HQ
HQ: Canada
SeedSeries A/BGrowth / Late StageNonprofit / grant-backed
Company-Led Drug Development & Commercialization
Portfolio Signals
Xpira Pharmaceuticals
Sep 22, 2022
Clairvoyant Therapeutics
Jul 7, 2022
Oscillate
Oscillate PLC is a publicly listed investment company on the Aquis Stock Exchange Growth Market. Its public corporate filings show it is incorporated in England and Wales, with a registered office in London, United Kingdom. Oscillate became relevant to the psychedelic ecosystem after broadening its investment strategy in 2021 to cover medical psychedelics. Public company materials indicate it has held an investment portfolio that included psychedelic-sector opportunities and that the company has been focused on early-stage companies in the space.
View Profile
Investor Category
Venture Capital
HQ
HQ: United Kingdom
SeedSeries A/BGrowth / Late Stage
Portfolio Signals
Public portfolio context is limited.
Otsuka
Otsuka Pharmaceutical Co., Ltd. is a Japanese pharmaceutical company within the Otsuka group, focused on creating and commercializing medicines and nutraceutical products. Its corporate profile lists its head office in Chiyoda-ku, Tokyo, Japan. The company describes itself as a total healthcare company with global operations and collaboration across academia and venture partners. In the psychedelic ecosystem, Otsuka is relevant because it has moved into adjacent neuropsychiatric and rapid-acting treatment areas through acquisitions and research collaborations. In 2025 it announced a joint research agreement with Keio University on infrastructure development for the social implementation of psychedelics in Japan, and in 2026 it announced and then completed its acquisition of Transcend Therapeutics, whose lead program TSND-201 is described as a rapid-acting neuroplastogen for PTSD.
View Profile
Investor Category
Institutional Investors
HQ
HQ: Japan
Growth / Late StagePublic MarketsMulti-StageNonprofit / grant-backed
Company-Led Drug Development & Commercialization
Portfolio Signals
Mindset Pharma
strategic acquisition · undisclosed · Sep 1, 2023
Transcend Therapeutics
strategic acquisition · $1.225 billion potential consideration · Mar 27, 2026
Palo Santo
Palo Santo is a venture capital fund focused on neuroscience and mental health innovation, with an explicit emphasis on next-generation psychedelic therapeutics and enabling technologies. Its public materials describe the firm as investing across novel CNS therapeutics, digital and clinical technologies, and related brain-health infrastructure. The firm is notable in the psychedelic ecosystem because its portfolio includes multiple companies working on psychedelic medicines, serotonergic agonists, ketamine-assisted care, and related CNS drug discovery. Palo Santo also highlights portfolio outcomes such as pharma acquisitions and FDA breakthrough designations across its neuroscience and psychedelic focus areas.
View Profile
Investor Category
Venture Capital
HQ
HQ: United States
SeedSeries A/BGrowth / Late Stage
Company-Led Drug Development & CommercializationEducational Platforms & ResourcesPractitioner-Led Care Organizations
Portfolio Signals
Gilgamesh Pharma
undisclosed
Transcend Therapeutics
undisclosed
Perceptive Advisors
Perceptive Advisors is a long-established life sciences investment manager based in New York. Its public materials describe a multi-strategy platform spanning life sciences, credit, capital solutions, and venture capital, with an emphasis on scientific diligence. In psychedelic medicine, Perceptive's role is healthcare-adjacent rather than dedicated. The firm has a confirmed COMPASS Pathways financing record, which supports inclusion without implying that psychedelics are a central thematic focus for the platform.
View Profile
Investor Category
Institutional Investors
HQ
HQ: United States
Multi-StagePublic MarketsNonprofit / grant-backed
Company-Led Drug Development & CommercializationEducational Platforms & Resources
Portfolio Signals
COMPASS Pathways
Series B · $80m · Apr 27, 2020
Peter Thiel
Peter Thiel is a partner at Founders Fund, a Silicon Valley venture capital firm, and is publicly associated with investing through that platform. Public company materials also identify him as a named investor in atai Life Sciences financing rounds. In the psychedelic ecosystem, Thiel is relevant primarily through atai Life Sciences, a clinical-stage biotech company developing psychedelic and non-psychedelic compounds for mental health indications. atai’s financing announcements describe him as a co-lead investor in the company’s Series C round and as one of the investors in a later convertible note financing.
View Profile
Investor Category
Angel Investors
HQ
HQ: United States
Series A/BGrowth / Late Stage
Portfolio Signals
atai Life Sciences
Series C financing (co-led) · $125m financing round · Nov 23, 2020
Phyto Partners
Phyto Partners is a venture capital firm based in Boca Raton, Florida. Its public materials describe the firm as investing in businesses around cannabis and, more recently, a psychedelic-focused fund called Phyto Psyche. In the psychedelic ecosystem, Phyto Partners matters as one of the earlier cannabis-to-psychedelics crossover investors, with public materials describing an investment thesis around brain health, neurowellness, and psychedelic therapeutics. The firm’s psychedelic content emphasizes a focus on privately held companies and drug-development-oriented opportunities.
View Profile
Investor Category
Venture Capital
HQ
HQ: United States
SeedSeries A/BGrowth / Late Stage
Portfolio Signals
Public portfolio context is limited.
Presight Capital
Presight Capital is a venture capital fund associated with Christian Angermayer and Apeiron Investment Group. It invests across sectors and stages, with public descriptions indicating a seed-to-growth orientation and a global remit. A public address on the firm’s website places it in West Hollywood, California, United States. Presight matters in the psychedelic ecosystem because it has appeared in the investor syndicate of Delix Therapeutics, a preclinical neuroscience company developing non-hallucinogenic analogs of psychedelics. Public reporting also links Presight to Compass Pathways, making it a visible backer around psychedelic drug development and adjacent neuropsychiatry.
View Profile
Investor Category
Venture Capital
HQ
HQ: United States
SeedSeries A/BGrowth / Late Stage
Company-Led Drug Development & Commercialization
Portfolio Signals
Delix Therapeutics
Series A · $70M round · Sep 27, 2021
Prime Movers Lab
Prime Movers Lab is a venture capital firm and family of funds focused on breakthrough scientific startups, with an emphasis on technically ambitious companies in areas like energy, transportation, infrastructure, manufacturing, human augmentation, and agriculture. Public filings and firm materials place its business in Jackson/Teton Village, Wyoming, in the United States. In the psychedelic ecosystem, Prime Movers Lab is relevant because it has explicitly backed psychedelic medicine and related neuroplasticity work, including Gilgamesh and a participation in Beckley Psytech’s most recent round through an SPV. Its public portfolio and ideas pages also show ongoing attention to psychedelics alongside adjacent neuroscience and biotech themes.
View Profile
Investor Category
Venture Capital
HQ
HQ: United States
SeedSeries A/BGrowth / Late Stage
Company-Led Drug Development & Commercialization
Portfolio Signals
Gilgamesh Pharma
private placement
Beckley Psytech
series round via SPV · undisclosed
Psych Capital
Psych Capital is a public-market psychedelic investor and media platform built around the medical psychedelics sector. Public filings describe it as the first pure-play psychedelic company to list in London, with an early-stage investment strategy focused on building and growing businesses within psychedelic healthcare. It matters in the psychedelic ecosystem because it combines market coverage, events, and capital allocation around the sector, rather than operating as a generalist fund. Public filings show it has invested in Awakn Life Sciences and has explored further early-stage opportunities in medical psychedelics.
View Profile
Investor Category
Venture Capital
HQ
HQ: United Kingdom
SeedSeries A/BGrowth / Late Stage
Company-Led Drug Development & Commercialization
Portfolio Signals
Awakn Life Sciences
private investment · £300,000 · Jun 11, 2021
PsyMed Ventures
PsyMed Ventures is a venture capital fund focused on brain and mental health innovation, with an explicit emphasis on psychedelic medicine, neurotechnology, precision psychiatry, digital therapeutics, and related frontier technologies. Public sources describe it as San Francisco-based and founded in 2020. In the psychedelic ecosystem, PsyMed Ventures appears as an early-stage backer of companies working across clinical infrastructure, therapeutics, and mental health platforms. Its publicly listed portfolio includes Journey Clinical, Maya Health, Mindstate Design Labs, and Reset Pharma, which places it across both psychedelic care delivery and drug-development-adjacent models.
View Profile
Investor Category
Venture Capital
HQ
HQ: United States
SeedSeries A/B
Company-Led Drug Development & CommercializationPractitioner-Led Care OrganizationsTechnology, Data, & Software Platforms
Portfolio Signals
Journey Clinical
Portfolio partner
Maya Health
Portfolio partner
Pura Vida Investments
Pura Vida Investments is a New York-based healthcare-focused investment firm and SEC-registered investment adviser that operates as a hedge fund / investment manager. Public sources describe it as market-neutral and oriented toward healthcare and life sciences, with activity across biotech, medical technology, diagnostics, and related therapeutics. In the psychedelic ecosystem, Pura Vida matters mainly as a public-market and crossover healthcare investor rather than a dedicated psychedelics specialist. It has been named in funding rounds for atai Life Sciences, one of the sector’s best-known public psychedelic companies, which suggests exposure to mental-health and psychedelic-adjacent drug development. Public materials place Pura Vida Investments in the New York area and describe it as a healthcare-focused, market-neutral investor with a broad life-science remit. Its publicly visible psychedelic relevance is indirect but meaningful: it has participated in at least one major atai Life Sciences financing, aligning the firm with the public-market side of psychedelic and mental-health therapeutics investing.
View Profile
Investor Category
Institutional Investors
HQ
HQ: United States
Growth / Late StagePublic MarketsMulti-StageNonprofit / grant-backed
Portfolio Signals
atai Life Sciences
Series D · undisclosed · Mar 3, 2021
QC Ventures
QC Ventures is the venture capital investment brand of Q·ADVISERS and describes itself as a deal-by-deal principal investor rather than a traditional fund. Its website says it has historically invested from Seed to Series A and beyond, with the ability to follow on at later stages. QC Ventures has publicly written about psychedelic and adjacent life-science opportunities, including atai Life Sciences and COMPASS Pathways. The firm says it has backed companies with scalable business models across industries and geographies, while also highlighting its role in the psychedelics value chain from research to clinics. The firm is associated with Vienna on its website and is tied to Q·CAPITAL VENTURES GmbH in the site footer, which points to an Austria-based operating presence. Its public materials also describe an active network of co-investors and strategic partners.
View Profile
Investor Category
Venture Capital
HQ
HQ: Austria
SeedSeries A/BGrowth / Late Stage
Portfolio Signals
atai Life Sciences
convertible round · $24M round · Apr 30, 2020
RA Capital Management
RA Capital Management is a large, multi-stage healthcare and life-sciences investment manager that funds and builds companies across a wide development spectrum. Its public materials stress evidence-based investing, company formation, and deep scientific diligence. For psychedelic medicine, RA Capital is relevant because it publicly lists Delix Therapeutics in its venture portfolio and Delix financing materials identify RA as a lead investor in the company's Series A. This is a strong psychedelic-adjacent record, while RA remains best framed as a broad life-sciences investor.
View Profile
Investor Category
Institutional Investors
HQ
HQ: United States
SeedSeries A/BGrowth / Late StagePublic MarketsMulti-StageNonprofit / grant-backed
Company-Led Drug Development & Commercialization
Portfolio Signals
Delix Therapeutics
Series A · $70 million · Sep 27, 2021
re.Mind
re.Mind Capital is a venture capital fund focused on mental health, brain health, and human flourishing, with a public website that lists its office in London and a Maltese company footer. Its site also describes it as a leading early-stage investor, and its legal pages identify re.Mind Capital Limited with an address in Sliema, Malta. In the psychedelic ecosystem, re.Mind matters because its public stories and investment context show activity across brain-computer interfaces and psychedelic-related therapeutics, including a featured story about Delix and a story page highlighting Small Pharma. Public references also describe the fund as part of Christian Angermayer’s Apeiron ecosystem and as an investor in psychedelic medicine alongside other neurotechnology and mental health themes.
View Profile
Investor Category
Venture Capital
HQ
HQ: Malta
SeedSeries A/BGrowth / Late Stage
Portfolio Signals
Public portfolio context is limited.
Roth Capital
Roth Capital Partners, LLC is a relationship-driven investment bank serving growth companies and their investors. It is headquartered in Newport Beach, California, with a global trading floor in Stamford, Connecticut. ROTH’s healthcare platform provides financing and strategic advisory services for public and private life sciences companies, including IPOs, follow-on offerings, PIPEs, registered directs, and confidentially marketed public offerings. In the psychedelic ecosystem, that makes it relevant primarily as a capital markets and advisory participant rather than a dedicated psychedelic specialist.
View Profile
Investor Category
Institutional Investors
HQ
HQ: United States
Growth / Late StagePublic MarketsMulti-StageNonprofit / grant-backed
Portfolio Signals
Public portfolio context is limited.
Route 66 Ventures
Route 66 Ventures is a private venture capital investor that backs early-stage companies, with a stated focus on digital health and wellness as well as financial technology. Public company information places the firm in Alexandria, Virginia, United States. In the psychedelic ecosystem, Route 66 Ventures is relevant because its portfolio includes Sensorium Therapeutics, a biotechnology company developing nature-inspired psychoactive medicines for mental health. That makes the firm a visible investor in adjacent mental health drug development rather than a generalist consumer or software fund.
View Profile
Investor Category
Venture Capital
HQ
HQ: United States
SeedSeries A/BGrowth / Late Stage
Portfolio Signals
Public portfolio context is limited.
RTW Venture Fund
RTW Venture Fund is a life sciences investment vehicle associated with RTW Investments, LP, which describes itself as a New York-based, global, full life-cycle investment firm focused on biopharmaceutical and medical technology innovation. Public RTW materials describe the platform as investing across the lifecycle, including venture, crossover, and public company investments. In the psychedelic ecosystem, RTW Venture Fund appears relevant mainly through adjacent neuropsychiatric and drug-development investing rather than a stated psychedelic-only mandate. RTW has also backed Amani Therapeutics, a company developing a therapy for serious neuropsychiatric disorders, which suggests interest in central nervous system programs that may overlap with psychedelic-adjacent clinical and translational work.
View Profile
Investor Category
Venture Capital
HQ
HQ: United States
SeedSeries A/BGrowth / Late Stage
Portfolio Signals
Public portfolio context is limited.
Stifel
Stifel is a U.S.-based diversified wealth management and investment banking firm with a corporate headquarters in St. Louis, Missouri. It serves individuals, institutions, and corporations through brokerage, research, investment banking, and related financial services. In the psychedelic ecosystem, Stifel is mainly relevant as a healthcare and biopharma capital-markets participant rather than a dedicated psychedelic specialist. Its public materials show active coverage of life sciences and biopharma, including venture banking and capital-raising activity in the sector, which makes it a potential advisor or financing counterparty for psychedelic drug developers as they move through public and late-stage markets.
View Profile
Investor Category
Institutional Investors
HQ
HQ: United States
Growth / Late StagePublic MarketsMulti-StageNonprofit / grant-backed
Portfolio Signals
Public portfolio context is limited.
Subversive Capital
Subversive Capital is a New York-based investment firm that operates across venture investing, public markets, activism, whistleblower financing, and ETFs. Public filings and the firm’s site describe it as active in early- and late-stage investments, with a focus on companies that operate in highly regulated or category-defining sectors. In the psychedelic ecosystem, Subversive is relevant because it has participated in atai Life Sciences financing rounds, including atai’s Series D in 2021. Its public positioning and board-level involvement with atai suggest a broader interest in regulated mental health and psychedelic-adjacent opportunities.
View Profile
Investor Category
Venture Capital
HQ
HQ: United States
SeedSeries A/BGrowth / Late Stage
Portfolio Signals
Public portfolio context is limited.
Tabula Rasa Ventures
Tabula Rasa Ventures is a venture capital firm focused on investing in health-related companies, including drug development, healthcare infrastructure, and digital therapeutics. Its website and profiles describe it as an early-stage investor with activity from pre-seed and seed through growth-stage financing. Public-facing sources point to New York, New York, in the United States as its base of operations. It matters in the psychedelic ecosystem because Tabula Rasa has explicitly backed psychedelic companies and frames part of its work around psychedelic and psychedelic-adjacent entrepreneurship. Its portfolio page includes Lykos Therapeutics and Natural MedTech, both tied to psychedelic drug development and research, and the firm has also described itself as supporting a psychedelic business incubator.
View Profile
Investor Category
Venture Capital
HQ
HQ: United States
SeedSeries A/BGrowth / Late Stage
Portfolio Signals
Lykos Therapeutics
Series A · $100M · Sep 29, 2023
Natural MedTech
Jan 1, 2021
The Conscious Fund
The Conscious Fund is a venture capital adviser and fund focused on early-stage psychedelic medicine and adjacent therapeutic innovation. Its public materials describe the firm as backing pioneers of psychedelic medicine, state of mind, and advanced therapeutics, and an SEC Form ADV identifies its legal entity as TCF Management LLC. The firm’s relevance in the psychedelic ecosystem comes from its explicit specialization in psychedelic medicine and its role as an early-stage investor in the sector. Public materials also indicate a global investment lens, with the firm describing itself as investing in global early-stage ventures in psychedelic medicine.
View Profile
Investor Category
Venture Capital
HQ
HQ: United States
SeedSeries A/BGrowth / Late Stage
Portfolio Signals
Mindleap Health
Seed · $11.5M · Feb 1, 2022
Tim Ferriss
Tim Ferriss is a U.S.-based angel investor, author, and podcast host who has been angel investing in tech and consumer packaged goods startups since 2008. His own site describes him as an early-stage technology investor/advisor and notes that most of his portfolio investments have been seed or Series A, with some later-stage positions. He matters in the psychedelic ecosystem because he has publicly backed psychedelic research and funding efforts, including major support for MDMA-assisted therapy and Johns Hopkins’ psychedelic research center. His public writing also says he shifted most of his focus away from startup investing and toward psychedelic science in 2015.
View Profile
Investor Category
Angel Investors
HQ
HQ: United States
SeedSeries A/BNonprofit / grant-backed
Academic & Non-Profit ResearchFoundations & Philanthropy
Portfolio Signals
Johns Hopkins Center for Psychedelic and Consciousness Research
philanthropic funding · part of $17 million in funding · Jan 1, 2019
MAPS / MDMA-assisted therapy fundraising
philanthropic challenge grant · $10 million challenge · Jun 12, 2020
Venrock Healthcare Capital Partners
Venrock Healthcare Capital Partners (VHCP) is Venrock’s later-stage healthcare investing program, focused on publicly held and late-stage private healthcare companies. Venrock is a venture capital firm founded in 1969, and public Venrock materials describe VHCP as a public and cross-over biotech fund. The firm’s team is based across Palo Alto and New York, with Venrock also operating in Boston. VHCP matters to the psychedelic ecosystem mainly as a broader life-sciences and drug-development investor rather than a dedicated psychedelics fund. Venrock’s public materials emphasize biotechnology, pharmaceuticals, and crossover/public healthcare investing, with team members who have experience across the full drug-development arc and in neurodegenerative disease programs.
View Profile
Investor Category
Venture Capital
HQ
HQ: United States
SeedSeries A/BGrowth / Late Stage
Portfolio Signals
Public portfolio context is limited.
Vine Ventures
Vine Ventures is an early-stage venture capital firm that describes its work as focused on health and wellness, with a particular interest in psychedelics, mental health, consciousness, and related life sciences themes. The firm says it was started in 2020 and operates with a presence in New York City and Tel Aviv. In the psychedelic ecosystem, Vine has positioned itself as a backer of companies and initiatives tied to psychedelic therapies and adjacent mental health models. Its public materials say it has led a large financing vehicle for MAPS to help bring MDMA to market for PTSD and that its team publishes and hosts content around psychedelic science and distribution.
View Profile
Investor Category
Venture Capital
HQ
HQ: United States
SeedSeries A/BGrowth / Late Stage
Community Networks & OutreachEducational Platforms & ResourcesMedia & Communication
Portfolio Signals
MAPS
SPV / private financing · almost $45M
What If Ventures
What If Ventures is a venture capital firm founded in 2020 and based in Frisco, Texas, United States. It invests from seed through pre-IPO and describes itself as focused on health, freedom, mental health, and disruptive healthcare, with some portfolio exposure to psychedelic and adjacent mental health companies. In the psychedelic ecosystem, What If Ventures matters because its portfolio includes companies such as Atai Life Sciences, Beckley Psytech, and 2A Biosciences, all of which are publicly associated with psychedelic medicine or psychedelic-adjacent drug development. The firm’s public portfolio and team pages show continued interest in mental health innovation, addiction, biomarkers, and psychiatric drug development.
View Profile
Investor Category
Venture Capital
HQ
HQ: United States
SeedSeries A/BGrowth / Late Stage
Company-Led Drug Development & Commercialization
Portfolio Signals
atai Life Sciences
Beckley Psytech
Y Combinator
Y Combinator is a startup accelerator and venture investor founded in 2005. It is based in San Francisco, California, and also lists Mountain View, California as a location on its public company profile. YC funds companies across software and biotech, and says it is especially comfortable funding life science projects at their earliest stage. In its current public biotech and drug-discovery materials, YC highlights work ranging from therapeutics to mental health and psychedelic medicine-adjacent companies.
View Profile
Investor Category
Venture Capital
HQ
HQ: United States
SeedSeries A/BGrowth / Late Stage
Company-Led Drug Development & CommercializationTechnology, Data, & Software Platforms
Portfolio Signals
Osmind
Mindstate Design Labs

Investor Landscape

Explore investor stakeholders by type, funding stage, and sector focus across the psychedelic ecosystem.

Investor Types

Angel Investors8

Institutional Investors25

Social-Impact Investors1

Venture Capital44

Strategic / L2-only2

Stage Focus

Growth / Late Stage64Seed50Series A/B50Multi-Stage29Public Markets25Pre-Seed4

Focus Areas

Drug Development79Digital Therapeutics & Platforms9Clinical Infrastructure7Manufacturing & Supply Chain3Mental Health Access Equity1Policy & Advocacy1

Investors

Specific Groups

Company Context

Investor Landscape

Investor Types

Stage Focus

Focus Areas

Company

Product

Legal

Company Context